Buy & Sell Avient Corporation (AVNT) – Avient Corporation Price Today
Aura AI Summary
Key Stats
- $3.42BMarket Cap
- TechnologySector
- -15.33%3M Drawdown
- $4.92BEnterprise Value
- 2.95%Dividend Yield
- 13 daysTypical Hold Time
Avient Corporation (AVNT) is currently valued at a market capitalization of $3.42B, with an enterprise value of $4.92B. Over the past 52 weeks, Avient Corporation has traded between a low of $27.48 and a high of $43.28, highlighting its annual price range. Over the past three months, Avient Corporation has recorded a drawdown of -15.33%, reflecting recent price volatility. Avient Corporation offers a dividend yield of 2.95%, with the most recent dividend of $0.28 paid on 18 Jun 26. On average, investors hold Avient Corporation for approximately 13 days, indicating typical investor behavior on the platform.
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Most Recent News
Muskrat Dam First Nation connects to Ontario power grid, ending diesel reliance and enabling community growth.
Muskrat Dam First Nation in northern Ontario was connected to the provincial power grid on April 9, 2026, allowing the community to shut down costly diesel generators. This connection removes previous power constraints, enabling new construction proj...

ASE Technology sees AI chip demand boost but insider selling and high valuation raise caution.
ASE Technology Holding Co Ltd reported strong growth driven by demand for AI chip packaging, with gross margins rising to 20.1% from 16.8% year-over-year. The company expects its advanced packaging revenue to exceed $3.5 billion in 2026, reflecting r...

Over 20 pharma firms actively develop 25+ drugs for acute kidney injury treatment, signaling strong pipeline growth.
More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapie...
